On July 25, 2023, the Board of Directors of Homology Medicines, Inc. approved a reduction in the Company?s current workforce by approximately 80 employees. The decision was based on cost-reduction initiatives intended to reduce the Company?s ongoing operating expenses and maximize shareholder value as the Company plans to pursue strategic options.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.75 USD | +2.29% | +7.35% | +153.56% |
05-09 | Q32 Bio Inc. Provides Corporate Update | CI |
04-11 | Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+153.56% | 324M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- QTTB Stock
- News Q32 Bio Inc.
- Homology Medicines, Inc. Approves Reduction in Workforce